Showing the latest 10 filings. Sign in to filter or browse the full history. View full history
Showing 10 of 54 filings.
18 Aug 2026 5 filings
Fundraising authorization
Members authorised the Board to raise funds up to ₹800 crore via equity shares or equity-linked securities.
Issuances may be via QIP, preferential allotment, rights issue, or combinations.
Aggregate size up to ₹800 crore.
Type of securities: Equity shares or other equity-linked securities.
Board/Committee to decide the specific issuance type.
Issuances subject to applicable regulatory/statutory approvals.
No pricing details disclosed.
Appointment of Independent Director
Appointment of Nakul Pasricha as Additional Non-Executive Independent Director.
Effective from July 10, 2026; 5-year term; not liable to retire by rotation.
Approved by AGM on August 18, 2026.
Not related to any Director.
Not debarred from holding the office.
27-year career; MD & CEO of PharmaSecure, anti-counterfeiting tech leader.
AGM Details
AGM held Aug 18, 2026 at 11:00 AM IST via VC/OAVM.
Voting cut-off date for shareholders: Aug 11, 2026.
Remote E-Voting period: Aug 14-17, 2026.
Resolutions & Voting
Item 1 (Ord): Adopt standalone and consolidated financial statements; 75.45% in favour, 24.55% against.
Item 2 (Ord): Re-appoint Aditya Pratap Jain as Director; 79.65% in favour, 20.35% against.
Item 3 (Special): Appoint Nakul Pasricha as Independent Director; 99.808% in favour, 0.192% against.
Item 4 (Special): Remuneration to Ajit Gulabchand as Non-Executive Chairman; 75.802% in favour, 24.198% against.
Item 5 (Ord): Ratification of remuneration of Cost Auditors for FY 2025-26; 99.818% in favour, 0.182% against.
Item 6 (Ord): Increase authorised share capital and alteration to MOA; 99.743% in favour, 0.257% against.
Item 7 (Special): Issue of Securities of the Company; 99.589% in favour, 0.411% against.
Dividend
No dividend proposed or declared.
Directors & Management Changes
Nakul Pasricha appointed as Independent Director.
Aditya Pratap Jain re-appointed as Director; retires by rotation.
Auditors & Capital Approvals
Cost Auditor remuneration ratified for FY 2025-26.
Authorised share capital increased; MOA capital clause altered.
AGM proceeding details
AGM held on August 18, 2026 at 11:00 a.m. via VC/OAVM.
AGM deemed to be conducted at the registered office as venue.
132 Members attended via VC, including corporate representatives.
No proxy facility was provided due to MCA circulars.
Quorum was present throughout the meeting.
Chairman Arjun Dhawan chaired in Ajit Gulabchand's absence.
Report of Board and financials for year ended March 31, 2026 were taken as read.
Statutory registers and secretarial certificate were available for electronic inspection.
Remote e-voting facility provided through NSDL to Members as of cut-off date.
11 Aug 2026 1 filing
Contract details
HCC wins a ~₹524.17 crore contract from NHPC Limited at Salal Power Station in Jammu & Kashmir.
Contract duration is 27 months.
Scope includes civil, hydro-mechanical and enabling works to rehabilitate undersluices.
Salal Power Station is NHPC's key hydroelectric asset.
HCC has delivered major projects in J&K, including 690 MW Salal and Uri-II.
Strategic relevance and impact
Contract reinforces HCC's role in hydro infrastructure and safety enhancements.
10 Aug 2026 1 filing
Filing status
This chunk contains only wrapper metadata; no substantive management remarks or Q&A content.
6 Aug 2026 2 filings
Financial Performance
Standalone turnover ₹982 Cr; standalone net profit ₹37 Cr in Q1 FY27.
Consolidated revenue ₹993 Cr; consolidated PAT ₹51 Cr in Q1 FY27.
EBITDA margin: standalone 10.7%; consolidated 10.6%.
Total income: standalone ₹1,012.7 Cr; consolidated ₹1,055.5 Cr.
Finance cost: standalone ₹79.8 Cr; consolidated ₹86.8 Cr.
Debt prepayment of ₹100 Cr planned in August 2026.
New order ₹127 Cr; L1 bids ₹2,124 Cr (HCC share ₹1,671 Cr).
4 bids worth ₹9,997 Cr under evaluation (HCC share ₹7,747 Cr).
Pipeline under pursuit ₹85,907 Cr.
Order Backlog & Opportunities
Order backlog stood at ₹12,976 Cr.
Diversified and robust orderbook supporting infra, metro, and hydro segments.
4 bids under evaluation; HCC share ₹7,747 Cr.
Pipeline under pursuit ₹85,907 Cr.
Operations Update
Indore Metro: TBM deployment advancing; piling and station excavation progressing.
Patna Metro PC05/PC06: casting yard development; TBMs due Sep–Dec 2026.
Agardanda Creek Bridge: land handover and clearances expected by Nov 2026.
Bhivpuri PSP: powerhouse excavation and upper intake excavation progressing.
Vishnugad Pipalkoti HEP: machine hall units 2–3; HRT excavation at 85%.
Tapovan Vishnugad HEP: HRT breakthrough achieved; remaining faces progressed.
Hindalco PS & PSS: pot shell prototype approved; bulk fabrication started.
Liquidity & Capital Structure
₹100 Cr debt prepayment planned in August 2026.
Issue overview
Rights issue of Equity Shares; no undersubscription or revision observed.
Objectives: debt repayment, JV repayment, working capital, GCP, and general corporate purposes.
Total issue size and net proceeds: no revision or undersubscription.
Deviation from objects: not applicable.
Utilisation of proceeds
Utilisation is as per offer document; no material deviations.
Repayment of borrowings: fully utilised.
Investment in Prolific Resolution Private Limited: fully utilised.
Augmenting working capital: fully utilised; delay of 72 days.
General Corporate Purpose: fully utilised; delay of 76 days.
02 crore reallocated from unutilised funds to GCP.
Issue expenses: fully utilised; some funds redirected to GCP.
Total unutilised funds: nil.
Governance and compliance
Government/statutory approvals not required.
Delays in deployment noted; no other material events.
Means of finance unchanged; no changes.
GCP
GCP allocation: 3.21 crore; 1.02 crore reallocated from unutilised funds.
Board approval for GCP allocation: not explicitly stated.
All GCP funds utilised.